MedTrace Logo

Single or Repeat Dose of G03-52-01 in Adult Subjects

NCT05348993 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 622

Last updated 2026-02-17

Study results available
· View outcomes & findings →

Summary

A Phase 2, randomized, double-blind, placebo-controlled single or repeat dose trial

Conditions

  • Healthy
  • Botulinum Toxin

Interventions

DRUG

G03-52-01

G03-52-01 administered intramuscularly

DRUG

Placebo

placebo

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • U.S. Army Medical Research and Development Command

    lead FED

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-15
Primary Completion
2025-02-18
Completion
2025-02-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05348993 on ClinicalTrials.gov